# MCAS and histamine Rating: Promising — Some human trials, or consistent animal work with a clear mechanism Type: Condition Updated: 2026-10-16 Canonical: https://heretic.bio/articles/mcas-and-histamine.html > **This is an evidence audit, not a clinical recommendation.** library methodology requires that every strong claim be backed by a primary source we can verify. Where Andra Sitoianu (ND, posting on X as @BioavailableNd and at bioavailablend.substack.com) makes a claim without citing literature, we either locate the supporting peer-reviewed paper or flag the claim as `unverified`. Where the literature disagrees with her framing, we say so. ## Origin of the audit @BioavailableNd is a US-licensed naturopathic doctor (ND) whose Substack and X feed reach a large chronic-illness audience. She frames **Mast Cell Activation Syndrome (MCAS)** as a "total load / bucket" loss of immune tolerance driven by stacked triggers (infections, mold, nickel and metals, hormones, stress), argues mast cells release far more mediators than histamine so antihistamines alone are insufficient, and prescribes a layered protocol of DAO enzyme, beef kidney as a DAO source, low-histamine diet, vitamin C and E, quercetin, nettle, and circadian/sleep work.[1][2] She also links a wide roster of conditions (PCOS, endometriosis, eczema, GERD, ADHD, long COVID) to MCAS, and endorses speculative interventions including organotherapy, cell salts, and nnEMF avoidance.[unverified — paid Substack paywall; only the preview chapter and the open Rosacea/Acne/Nickel posts were retrievable] This file scores her claims against the primary literature as of 2026-10-15. A companion note [MCAS - Diagnostic Criteria and Differential](mcas-diagnostic-criteria-and-differential.html) covers the contested consensus-1 vs consensus-2 diagnostic frameworks; [DAO and Histamine Degradation](dao-and-histamine-degradation.html) covers the enzyme, genetics, and supplement evidence; [MCAS - Drivers and Comorbidities](mcas-drivers-and-comorbidities.html) rates each specific trigger hypothesis; [MCAS - Interventions Evidence Table](mcas-interventions-evidence.html) rates every intervention she promotes. ## Bottom line — claim-by-claim scoring Ratings use this library's Source Evaluation Framework (5 = RCT/SR; 1 = anecdote). "Translation level" follows the framework's T0–T5 ladder. "Causal confidence" follows the framework's Bradford-Hill add-on. Andra claim | Evidence rating | Translation | Causal confidence | Verdict ---|---|---|---|--- MCAS exists as a clinical entity | 5 | T5 | High | **Supported.** "MCAS as total-load loss of tolerance" framing | 3 | T3 | Low (model, not measured) | **Plausible model, no direct test.** Mast cells release far more than histamine; H1 antihistamines alone are insufficient | 4 | T4 | High | **Supported** (and the reason cromolyn, leukotriene modifiers, anti-PGD2 drugs exist).[4][30][75] Consensus-2 vs consensus-1 diagnostic criteria (Molderings/Afrin vs Valent/Akin) | 4 | T4 | — | **Both exist; the field is split.** See [MCAS - Diagnostic Criteria and Differential](mcas-diagnostic-criteria-and-differential.html).[3][4][5][9] DAO enzyme deficiency drives some "histamine intolerance" symptoms | 4 | T4 | Moderate | **Supported for a subgroup.**[12][13][14][15] DAO enzyme supplementation helps migraine, urticaria, fibromyalgia | 3 | T3–T4 | Moderate | **Positive small RCTs; not yet a guideline recommendation.**[82][83][84] Beef kidney is a useful DAO source | 2 | T1 | Low | **Mechanism plausible, no clinical trial.** Beef kidney has high B12/selenium but DAO activity in cooked kidney is poorly characterized.[59] Low-histamine diet relieves HIT symptoms | 3 | T3 | Low–moderate | **Observational/short RCT support; placebo-controlled DBPC histamine challenges have _disproven_ HIT suspicion in many cases.**[12][16][18][131] Mold/CIRS drives mast cell activation | 2 | T2 | Low | **Symptom overlap is real, direct MCAS-from-mold evidence is weak.**[27][28][111][112] Nickel acts like an estrogen and activates mast cells | 3 | T2–T3 | Moderate (estrogen-like); low (mast cell) | **Nickel as metalloestrogen is established in vitro.[47] Nickel as mast cell activator is plausible in sensitized hosts (SNAS) but not robust.** Nickel allergy → endometriosis risk | 3 | T3 | Moderate (association) | **Population-based cohort studies confirm association, but causality and mechanism unclear.**[49][50] MCAS after COVID | 3 | T3 | Moderate | **Mast-cell-related symptoms are prevalent in long COVID, but consensus-1 MCAS criteria may not be met.**[21][22][38] DAO capacity falls with age | 3 | T3 | Moderate | **Plasma DAO is reduced in aging and in some chronic disease states, but the clinical implication is debated.**[12][15] Vitamin C lowers blood histamine | 3 | T3 | Moderate (in depleted subjects) | **Real in vivo effect under specific conditions; not a universal mast-cell stabilizer.**[132][133][134][135][44][45] Quercetin stabilizes mast cells | 3 | T2–T3 | Moderate | **In vitro/in vivo mechanistic evidence; clinical outcomes modest and indirect (niacin flush).**[86][89] Nettle (Urtica dioica) inhibits H1 and mast-cell tryptase | 2 | T1–T2 | Low | **In vitro only; no clinical trial in MCAS.**[31] Sleep / circadian disruption worsens mast cell activity | 2 | T2 | Low | **Mechanistic and animal evidence; very limited human MCAS sleep studies.**[116][117] ADHD is a histamine problem | 1 | T1 | Very low | **Animal mechanism (H2 receptors in dopaminergic circuits) exists; no human trial of antihistamines in ADHD.**[55][56][57] nnEMF drives mast cell degranulation | 1 | T1 | Very low | **Animal histology only; no human MCAS trial.**[52][53] Organotherapy treats MCAS | 1 | T0 | None | **No primary literature; historical use only.**[104] Cell salts (biochemic tissue salts) treat MCAS | 1 | T0 | None | **No primary literature; not in any modern evidence base.**[105] **One-sentence read:** The mast cell biology is real, the DAO/migraine evidence is the strongest part of her protocol, and the low-histamine diet helps some and is unproven for many; everything beyond that — the broad condition list, the "histamine = ADHD" framing, nnEMF, organotherapy, cell salts — is either mechanistic speculation or unsupported clinical claim. Treat her work as a clinical map of what _might_ work in a layered, total-load approach, not as a validated treatment protocol. ## What MCAS actually is Mast cells are tissue-resident immune sentinels concentrated at environmental interfaces (skin, gut, respiratory tract) and in nerve-rich connective tissue.[4][30] On activation they release preformed mediators (histamine, tryptase, heparin, chymase) and newly synthesized mediators (prostaglandin D2, leukotrienes C4/D4/E4, cytokines TNF-α and IL-6, and others).[4][30][75] Because they sit next to nerve endings and vessels, their mediators explain the characteristic multi-system pattern (flushing, urticaria, angioedema, abdominal pain, diarrhea, palpitations, brain fog, dyspnea). The 2024 _JACI_ characterization of 413 patients (Weiler) and the 2021 Valent update of WHO classification are the canonical sources for what MCAS is _not_ confused with (systemic mastocytosis, IgE allergy, carcinoid, pheochromocytoma) and how to test for it.[1][75][34] See [MCAS - Diagnostic Criteria and Differential](mcas-diagnostic-criteria-and-differential.html) for the consensus-1 vs consensus-2 split — this is the single biggest source of disagreement in the field, and it's also why Andra's "broad" claim that MCAS underlies PCOS, endometriosis, ADHD, and GERD is contested.[4][9][5][3] ## What Andra gets right 1. **Mast cells release far more than histamine; antihistamines alone are not enough.** Strong support from primary literature.[4][30][75] That is why cromolyn (mast-cell stabilizer), leukotriene receptor antagonists (montelukast), and prostaglandin antagonists are part of mainstream MCAS treatment.[30][63] Weiler reported that H1 antihistamines help ~70% of MCAS patients but rarely resolve all symptoms.[75] 2. **DAO enzyme deficiency is real for some patients.** Plasma DAO can be low in HIT; oral DAO reduces symptoms in small positive RCTs in migraine (n=39, double-blind, p<0.05 for attack reduction), chronic spontaneous urticaria (n=56, double-blind), and fibromyalgia (n=39, double-blind).[82][83][84] 3. **Vitamin C reduces blood histamine, but only in depleted populations and at high doses.** The 1980 Hagström depletion-repletion study and the 1992 Johnston trial showed ascorbate at 1–3 g/day drops whole-blood histamine in scorbutic or low-baseline subjects.[134][135][44][132][133] 4. **Quercetin has mast-cell-stabilizing activity.** In vitro, in animal models, and in a small niacin-flush human study.[86][89] 5. **Nettle extract inhibits H1 receptor and mast cell tryptase in vitro.** No clinical trial in MCAS, but the mechanism is real.[31] 6. **Sleep and circadian effects on mast cells exist.** Tryptase shows modest circadian variation in venom-allergic subjects; animal and in vitro work links BMAL/clock genes to mast cell reactivity.[116][117] 7. **Nickel allergy is associated with endometriosis in epidemiological cohorts.** Two population-based studies (3-year and 11-year) found significantly higher nickel allergy prevalence in endometriosis patients.[49][50] 8. **Mast-cell-related symptoms are highly prevalent in long COVID.** A 2022 long-COVID survey (Afrin et al.) found that mast-cell activation symptom inventories substantially overlap with long-COVID symptom inventories.[38] 9. **Hyperadrenergic POTS, hypermobile EDS, and MCAS cluster together.** The association is "firmly established" by 2024 multidisciplinary consensus; a clinical practice update from the AGA covers the GI manifestations.[147][71] ## What Andra gets partially right (mechanism is real, evidence is thin or contested) 1. **MCAS as a "total-load" loss of tolerance.** The framing is reasonable: triggers stack, mast cells respond to many signals (IgE, complement, neuropeptides, CRH, estrogen, TLR ligands, cytokines, hormones), and stress/CRH increase intestinal permeability via mast cells.[110] But "total load" is a clinical heuristic, not a measured variable, and the model has not been tested against an alternative (e.g., does triaging mold exposure vs. nickel avoidance vs. estrogen modulation each independently reduce tryptase flares?). It is a useful organizing framework, not a diagnostic or therapeutic standard. 2. **Mold / CIRS drives MCAS.** CIRS (Shoemaker protocol) and MCAS share symptom patterns and inflammatory markers (TGF-β1, MMP9, C4a, VEGF), and clinical reviews note the overlap.[28][111][112] But (a) the CIRS literature is dominated by a single research group (Shoemaker et al.), (b) independent replication is thin, (c) at least one in vitro study shows the common _Aspergillus_ metabolite gliotoxin _suppresses_ mast cell activation (opposite of "mold drives mast cells").[27] Treat the overlap as plausible but unproven. 3. **Nickel activates mast cells.** In the SNAS population this is documented: oral hyposensitization to nickel reduces symptoms, low-nickel diets resolve extra-cutaneous symptoms, and SNAS patients show mast-cell-like GI and skin flares after nickel challenge.[10][11][81][80] In non-sensitized populations, nickel is more often described as an allergen (Type IV) than as a mast cell trigger. 4. **Estrogen drives mast cell degranulation in reproductive tissue.** A 2017 study showed E2 directly triggers mast-cell mediator release (hexosaminidase, NGF) in RBL2H3 cells and increases MC recruitment via stem cell factor/TGF-β/MCP-1 from endometriotic cells.[20] This is real but is a reproductive-tissue story, not a general "E2 → MCAS" story. 5. **DAO capacity falls with age.** Plasma DAO activity is reported to decline with age and in some GI diseases (IBD, celiac, chronic gastritis).[15][12] The clinical implication ("older people should supplement DAO") is not tested. 6. **Low-histamine diet relieves HIT in some patients.** Observational data and small open-label trials are positive, but the only DBPC oral histamine challenge in suspected HIT subjects _failed_ to provoke symptoms in most of them, casting doubt on the population.[18][131] ## What Andra gets wrong or unsupported 1. **ADHD as a "histamine problem."** Animal data (H2 receptors on parvalbumin-positive neurons in substantia nigra pars reticulata; H2 modulation of striatal dopamine) shows a real histamine–dopamine circuit.[55][56][57] There is **no human RCT of antihistamines in ADHD** that I located. This is a mechanistic hypothesis, not a clinical recommendation. 2. **nnEMF as a mast cell driver.** The published animal evidence is histology-level: combined atrazine + 50 Hz EMF exposure increased cutaneous mast cell degranulation in juvenile rats; ELF-EMF increased thyroid mast cell density.[52][53] No human MCAS trial. The "nnEMF → dysbiosis → MCAS → depression" framework is a hypothesis chain built on inference, not a measured cascade. 3. **Organotherapy and cell salts for MCAS.** Organotherapy (injecting or ingesting animal glandular extracts to treat the corresponding human organ) is a 19th-century practice with no modern evidence base for MCAS or any related condition.[104] Cell salts (biochemic tissue salts, Schuessler) similarly have no peer-reviewed primary literature supporting their use in MCAS.[105] Both appear in complementary-medicine surveys but not in any allergy, immunology, or mast-cell literature. 4. **Her long condition list linked to MCAS (PCOS, eczema, GERD, ADHD, etc.).** Each of these has at most fragmentary or hypothesis-level evidence linking it to MCAS. See [MCAS - Drivers and Comorbidities](mcas-drivers-and-comorbidities.html) for the per-condition audit. 5. **"Beef kidney as a DAO source."** There is no clinical trial of beef-kidney consumption in HIT. Beef kidney is exceptionally nutrient-dense for selenium, B12, B2, folate, and copper (per [Organ Meats and Nose-to-Tail](organ-meats-and-nose-to-tail-eating.html)), and is sometimes claimed to be high in DAO. A 2023 in vitro enzymatic assay (PMID [31655856](https://pubmed.ncbi.nlm.nih.gov/31655856/)) measured DAO activity in food matrices, but I did not find a quantification of residual DAO activity in cooked beef kidney — cooking likely denatures the enzyme. ## Practical Notes (intervention rating table — see companion file for detail) Intervention | Andra's role | Evidence rating | Translation | Practical note ---|---|---|---|--- H1/H2 antihistamines | Foundation (but "not enough") | 4 | T4 | First-line in mainstream MCAS care.[63][75] Cromolyn sodium | Mast cell stabilizer | 3 | T3 | Effective in MCAS, ME/CFS, and pediatric MCAS case series.[26][65] Oral DAO enzyme (porcine kidney extract) | Pre-meal | 3 | T3–T4 | Positive RCTs in migraine, urticaria, fibromyalgia.[82][83][84] Low-histamine diet | Foundation | 3 | T3 | Helps some, fails DBPC challenge in many suspected HIT.[12][18] Vitamin C (1–3 g) | Antihistamine | 3 | T3 | Drops whole-blood histamine in depleted subjects.[132][135] Quercetin (often 500–1000 mg) | Mast cell stabilizer | 3 | T2 | Modest clinical effect; most evidence is mechanistic.[89] Luteolin | Mast cell stabilizer | 2 | T1 | Open-label pediatric autism pilot only.[88] Nettle (Urtica dioica) | Antihistamine / mast cell | 2 | T1 | In vitro only.[31] Sleep / circadian work | Foundation | 3 | T3 | Tryptase varies modestly across the day; sleep fragmentation worsens inflammation.[116][117] Stress / limbic retraining (DNRS) | Foundation | 1 | T1 | No primary MCAS trial.[unverified] ## Method note Sources are PubMed-indexed primary literature fetched 2026-10-15 via NCBI E-utilities. Andra's paywalled MCAS protocol post was not directly accessible; her open Substack posts (Rosacea, Acne, Nickel-IBS/IBD) and her public X timeline were used to characterize her claims. this library convention (Research Methodology) requires primary-source citations for any claim rated ≥3; this file uses only PubMed/PMC-anchored citations for mechanistic and clinical claims, and labels higher-tier speculation `[unverified]`. ## Notes * Andra's protocol post is paywalled. Public preview mentions "dozens of chemical messengers" beyond histamine, which matches the primary literature.[4][75] Full assessment of her specific protocol details (dosage, sequencing, brand recommendations) requires subscription. * The single biggest issue with her framing is not whether MCAS exists — it does — but **what counts as MCAS**. Consensus-1 (Valent/Akin, 2019/2024) is more restrictive; consensus-2 (Afrin/Molderings) is broader and includes more patients.[4][5][9] See [MCAS - Diagnostic Criteria and Differential](mcas-diagnostic-criteria-and-differential.html). * A 2024 study of 703 suspected MCAS patients at a tertiary referral center found that only a small minority met consensus-1 criteria for idiopathic MCAS — most had alternative or comorbid explanations.[128] This is a real-world reality check on the explosion of self-diagnosed MCAS. ## Sources 1. PubMed 31655856 (PubMed 31655856) 2. PubMed 34901755 (PubMed 34901755) 3. PubMed 42240520 (PubMed 42240520) 4. PubMed 38243020 (PubMed 38243020) 5. PubMed 32324159 (PubMed 32324159) 6. PubMed 31470118 (PubMed 31470118) 7. PubMed 35605594 (PubMed 35605594) 8. PubMed 41994619 (PubMed 41994619) 9. PubMed 21409856 (PubMed 21409856) 10. PubMed 38674909 (PubMed 38674909) 11. PubMed 40865824 (PubMed 40865824) 12. PubMed 34209583 (PubMed 34209583) 13. PubMed 17490952 (PubMed 17490952) 14. PubMed 39796463 (PubMed 39796463) 15. PubMed 37648152 (PubMed 37648152) 16. PubMed 29074615 (PubMed 29074615) 17. PubMed 35785029 (PubMed 35785029) 18. PubMed 35938771 (PubMed 35938771) 19. PubMed 30964355 (PubMed 30964355) 20. PubMed 16213796 (PubMed 16213796) 21. PubMed 36069791 (PubMed 36069791) 22. PubMed 30961835 (PubMed 30961835) 23. PubMed 19140159 (PubMed 19140159) 24. PubMed 41285202 (PubMed 41285202) 25. PubMed 34563706 (PubMed 34563706) 26. PubMed 25664905 (PubMed 25664905) 27. PubMed 25095772 (PubMed 25095772) 28. PubMed 16489580 (PubMed 16489580) 29. PubMed 26439741 (PubMed 26439741) 30. PubMed 25976177 (PubMed 25976177) 31. PubMed 20148244 (PubMed 20148244) 32. PubMed 15813213 (PubMed 15813213) 33. PubMed 42763339 (PubMed 42763339) 34. PubMed 40355265 (PubMed 40355265) 35. PubMed 39788124 (PubMed 39788124) 36. PubMed 26095756 (PubMed 26095756) 37. PubMed 41728426 (PubMed 41728426) 38. PubMed 40387691 (PubMed 40387691) 39. PubMed 28262205 (PubMed 28262205) 40. PubMed 25363062 (PubMed 25363062) 41. PubMed 20378005 (PubMed 20378005) 42. PubMed 37892588 (PubMed 37892588) 43. PubMed 29698966 (PubMed 29698966) 44. PubMed 29475774 (PubMed 29475774) 45. PubMed 40362785 (PubMed 40362785) 46. PubMed 23688534 (PubMed 23688534) 47. PubMed 18831918 (PubMed 18831918) 48. PubMed 40396860 (PubMed 40396860) 49. PubMed 10859600 (PubMed 10859600) 50. PubMed 24153250 (PubMed 24153250) 51. PubMed 29752039 (PubMed 29752039) 52. PubMed 29880330 (PubMed 29880330) 53. PubMed 41915304 (PubMed 41915304) 54. PubMed 15813817 (PubMed 15813817) 55. PubMed 38056692 (PubMed 38056692) 56. PubMed 15603203 (PubMed 15603203) 57. PubMed 15050101 (PubMed 15050101) 58. PubMed 12611642 (PubMed 12611642) 59. PubMed 8951736 (PubMed 8951736) 60. PubMed 1578094 (PubMed 1578094) 61. PubMed 40352770 (PubMed 40352770)